Novartis Clozaril, Generic Registry Merger Could Clarify Potential Risk

Combining Novartis' Clozaril white blood cell patient registry with generic clozapine databases could provide a clearer picture of the potential risk of moving to a less frequent monitoring schedule, FDA's Psychopharmacologic Drugs Advisory Committee agreed June 16